Thermo Fisher consolidates viral vector work in Massachusetts, cuts 160 workers
Thermo Fisher is closing a factory in Lexington, MA, and merging operations with a newer facility in Plainville, MA, to “optimize” viral vector production, a spokesperson told Endpoints News. The...
View ArticleFDA lifts hold on Novavax vaccines after adverse event reclassified as ALS
The FDA has removed a clinical hold on Novavax’s flu-Covid combination shot and standalone flu vaccine, less than a month after it was first instituted. The vaccine maker
View ArticleRapt cuts immunology program following clinical holds
Rapt Therapeutics is officially shelving its mid-stage immunology candidate after a case of liver failure triggered clinical holds earlier this year. Back in February, the FDA placed holds on two Phase...
View Article23andMe to shut down its therapeutics division
23andMe is closing its therapeutics division and will wind down ongoing clinical trials, the struggling genetic testing company said Monday evening. The company said it’s exploring all strategic...
View ArticleNeurogene's stock falls in post-market trading after early data in Rett syndrome
Neurogene's stock {$NGNE} fell 35% in post-market trading on Monday after a Rett syndrome patient who received a high dose of the company's gene therapy experienced a serious adverse event,...
View ArticleGSK acquires Parkinson's small molecule from Vesalius
GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another undisclosed neurodegenerative condition with Flagship-founded Vesalius...
View ArticleNovartis pays $150M upfront to Schrödinger in new drug deal
Novartis will pay $150 million upfront to Schrödinger, in a pact announced Tuesday to work together on several preclinical drug programs. Founded in 1990, Schrödinger has been developing and selling...
View ArticleSanofi, OpenAI, Formation Bio launch Muse, an AI tool for patient recruitment
A flashy collaboration between Sanofi, OpenAI and Formation Bio produced its first AI-powered tool, aiming to speed up the process of recruiting patients into clinical trials. The tool is called Muse...
View ArticleTrace Neuroscience raises $101M for ALS and other neuro conditions
Trace Neuroscience, a startup spun out of Maze Therapeutics' pipeline, broke cover Tuesday morning with $101 million in funding to develop treatments for amyotrophic lateral sclerosis and other...
View ArticleRoche teams with Flare Therapeutics on transcription factors
Roche is aligning with Flare Therapeutics to work on small molecules for cancer by going after transcription factor targets, the companies said Tuesday morning. Cambridge, MA-based Flare has a...
View ArticleAlentis nabs $181M to broaden Claudin's scope in ADCs
Swiss biotech Alentis Therapeutics thinks it can expand the reach of the Claudin family in oncology, and half a dozen new investors are helping back the idea with a $181.4 million Series D. Tuesday's...
View ArticleAstraZeneca budgets another $2B to boost manufacturing and R&D in US
Among a flurry of third-quarter updates on Tuesday, AstraZeneca said it is earmarking an additional $2 billion to add 1,000 new jobs in the US. This is on top of the ...
View ArticleBayer not eyeing new deals to address Xarelto sales erosion
Bayer reiterated its plans to ride out the generic-driven sales decline of its thrombosis drug Xarelto, as the company’s shares plummeted to a record low because of lackluster third-quarter earnings....
View ArticleAstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successor
AstraZeneca and Daiichi Sankyo are changing the approval submission strategy for its planned Enhertu successor, datopotamab deruxtecan (Dato-DXd), after a few missed trials. The companies voluntarily...
View ArticleExclusive: GV-backed Medicaid startup Diverge Health raises $52M
A startup that helps low-income Medicaid members get the care they need and supports the doctors who work with them has raised $52 million, it confirmed to Endpoints News. Alphabet's venture arm GV led...
View ArticleApollo makes a deal worth up to $926M; Abeona resubmits gene therapy
Plus, news about Centessa, Autolus Therapeutics, Zucara Therapeutics, Vindur Tx, Vittoria Biotherapeutics and the MD Anderson Cancer Center: Apollo Therapeutics’ cardio-metabolic pact: The company will...
View ArticleMerck KGaA plans China submission after late-stage win for tumor drug
Merck KGaA’s experimental treatment for patients with tenosynovial giant cell tumors hit the primary endpoint in a Phase 3 study, and the company plans to submit the drug for approval in China with its...
View ArticleFDA commissioner warns of risk to agency under RFK Jr. influence
With just a few months to go before he likely steps down, President Biden's FDA Commissioner Rob Califf weighed in on how the agency might be affected by the incoming administration. Califf, while not...
View ArticleFDA denies Ocaliva full approval, but Intercept hopes to keep drug on market
The FDA rejected the full approval submission for Intercept Pharmaceuticals and Alfasigma’s primary biliary cholangitis treatment Ocaliva after safety concerns dogged the product, casting its future...
View ArticleMerck, AstraZeneca tout Phase 3 win for Koselugo in neurofibromatosis
Merck and AstraZeneca are hoping to expand the label of their MEK inhibitor Koselugo to certain adult patients with neurofibromatosis type 1 following a successful Phase 3 study. The companies
View Article